IGEA S.p.A.
IGEA S.p.A. is an Italian privately-held biomedical company that develops and sells proprietary biophysical therapy devices (PEMF, CCEF, LIPUS, electroporation) across orthopaedics, electrochemotherapy, and gene therapies, serving hospitals and clinics in 17+ European countries through direct sales and a rental subscription model.
- Company typePrivate
- Founded1982
- HeadquartersCarpi (MO), Italy
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What IGEA S.p.A. does
IGEA S.p.A. is a privately-held Italian biomedical company headquartered in Carpi, Modena, that designs, manufactures, and distributes proprietary medical devices for biophysical therapy across three divisions: orthopaedic therapies, electrochemotherapy, and gene therapies. The company builds pulsed electromagnetic field (PEMF), capacitive coupling electric field (CCEF), low-intensity pulsed ultrasound (LIPUS), and reversible electroporation devices — including Biostim, OsteoSpine, I-ONE, Biostim SPT, OsteoBit, FAST, Cliniporator, Cliniporator Vitae, CLINIPORATOR FULL, and Genedrive — that deliver patented, indication-specific signal parameters engineered to stimulate bone and cartilage repair, treat solid tumours, and enable nucleic acid vaccine delivery. All therapeutic signals are patented, supported by four decades of preclinical and clinical research conducted in collaboration with named institutions including the Rizzoli Orthopaedic Institute and the Universities of Modena, Naples, and Verona, with over 500,000 patients treated cumulatively.
IGEA sells and rents these devices to hospitals, clinics, and orthopaedic treatment centers through a direct field sales motion supplemented by a European distribution network covering 17+ countries (Austria, Belgium, Czech Republic, France, Germany, Greece, Ireland, Italy, Malta, Northern Ireland, Poland, Portugal, Romania, Scotland, Spain, the Netherlands, and the UK). Revenue is generated through one-time device purchases and a 'Rent or Buy' monthly subscription rental model, with a dedicated Medical Department supporting healthcare professional engagement and clinical evidence dissemination. The company was founded by Dr. Ruggero Cadossi, who continues to lead as Chair, Medical Director, and R&D Director alongside a medically credentialed senior team. IGEA has no disclosed institutional investors, no public listing, and reports 177 employees with no published financials.
IGEA S.p.A. firmographics
Firmographics- Name
- IGEA S.p.A.
- Legal name
- IGEA S.p.A.
- Website
- https://igeamedical.com
- Company type
- Private
- Founded year
- 1982
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- IGEA S.p.A. is an Italian privately-held biomedical company that develops and sells proprietary biophysical therapy devices (PEMF, CCEF, LIPUS, electroporation) across orthopaedics, electrochemotherapy, and gene therapies, serving hospitals and clinics in 17+ European countries through direct sales and a rental subscription model.
- Ownership category
- akta.pro rank
IGEA S.p.A. industry classification
Industry- Product category
- Biophysical Therapy Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industry
- Pain Management (Spine & Musculoskeletal) (HLAKALAM)
Keywords
Where IGEA S.p.A. is headquartered
LocationHeadquarters
- HQ city
- Carpi (MO)
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
IGEA S.p.A. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: Sale of proprietary biophysical therapy medical devices including Biostim, OsteoSpine, I-ONE, Biostim SPT, OsteoBit, FAST for orthopaedics, Cliniporator for electrochemotherapy, and gene therapy equipment. Products are sold directly to healthcare facilities and hospitals.
- Device Rental: The company offers a 'Rent or Buy' model allowing healthcare facilities to rent medical devices rather than purchase outright, providing flexible access to biophysical therapy equipment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Purchase option for medical devices |
| Subscription | Monthly | Rental option for medical devices |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
IGEA S.p.A. product offering
Product offeringCore offering
IGEA S.p.A. develops, manufactures and sells proprietary biophysical therapy medical devices across three therapeutic divisions: Orthopaedic Therapies (Biostim®, OsteoSpine®, I-ONE®, Biostim® SPT, OsteoBit®, FAST®) using PEMF, CCEF and LIPUS physical stimuli to promote bone and cartilage healing; Electrochemotherapy (Cliniporator®, Cliniporator® Vitae) using reversible electroporation for treatment of solid tumours and vascular malformations; and Gene Therapies (CLINIPORATOR® FULL, Genedrive) using tissue electroporation for nucleic acid vaccine delivery. The devices are sold and rented to hospitals, clinics and orthopaedic treatment centers, primarily across Europe.
Product overview
IGEA S.p.A. is a biomedical company and world leader in biophysical therapies, offering a portfolio of medical devices across three therapeutic divisions: Orthopaedic Therapies (Biostim®, OsteoSpine®, I-ONE®, Biostim® SPT, OsteoBit®, FAST®), Electrochemotherapy (Cliniporator®, Cliniporator® Vitae, Electrodes), and Gene Therapies (CLINIPORATOR® FULL, Genedrive, Electrodes and Accessories). These products utilize physical energy modalities including Pulsed Electromagnetic Fields (PEMF), Capacitive Coupling Electric Fields (CCEF), Low-Intensity Pulsed Ultrasound (LIPUS), and reversible electroporation for therapeutic purposes in orthopaedic, oncological, and genetic medicine applications.
Differentiator
Problem solved
Functional benefit
Brands
- IGEA Medical: The commercial/trade name used for the company's medical device and biophysical therapy business operations.
Products and services
- Biostim® Pulsed Electromagnetic Field (PEMF) therapy device for osteogenesis stimulation, promoting bone tissue repair and accelerating fracture healing. Targeted at orthopaedic departments in hospitals and clinics.
- OsteoSpine® Capacitive Coupling Electric Field (CCEF) therapy device for the treatment of osteoporotic vertebral fractures and control of acute and chronic pain. Targeted at orthopaedic and spine specialists.
- I-ONE® Pulsed Electromagnetic Field (PEMF) therapy device with a joint-specific signal for control of the articular environment, treating knee bone edema, osteoarthritis and supporting cartilage repair. Targeted at orthopaedic specialists and rheumatologists.
- Biostim® SPT Pulsed Electromagnetic Field (PEMF) therapy device for osteogenesis stimulation, specifically designed for revision hip replacement recovery and osteonecrosis treatment. Targeted at orthopaedic surgery departments.
- OsteoBit® Capacitive Coupling Electric Field (CCEF) therapy device for treatment of fresh and unoperated fractures, delayed union, pseudarthrosis, and stress fractures. Targeted at trauma and orthopaedic departments.
- FAST® Low-Intensity Pulsed Ultrasound (LIPUS) therapy device for accelerated healing of recent tibia fractures, delayed unions, and pseudarthrosis. Targeted at orthopaedic and trauma clinics.
- Cliniporator® Electrochemotherapy device utilising reversible electroporation for the treatment of primary and secondary solid tumours. Targeted at surgical oncology departments and cancer centers.
- Cliniporator® Vitae Electrochemotherapy device for tumour treatment and vascular malformations using reversible electroporation technology. Targeted at oncology and vascular surgery departments.
- CLINIPORATOR® FULL Gene therapy device for tissue electroporation enabling delivery of nucleic acid vaccines and therapeutic applications. Targeted at gene therapy research labs and translational research centers.
- Genedrive Gene therapy technology platform for electroporation-based delivery of genetic material. Targeted at research hospitals, biotech laboratories and translational research teams.
Companies that use IGEA S.p.A.
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
IGEA S.p.A. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
IGEA S.p.A. partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
IGEA S.p.A. competitors and assessment
Company assessmentBroad incumbents
- Stryker: Major orthopedic devices conglomerate with biologic and regenerative adjacencies. Broad incumbent in the orthopaedic space that competes for hospital orthopaedic budgets targeted by IGEA's portfolio.
- Zimmer Biomet: Global orthopedic medtech incumbent that distributes bone stimulation and biologic solutions for fracture healing. Broader portfolio player with overlapping orthopaedic stimulation offerings.
- Enovis (DJO Global): Large orthopedic and recovery sciences platform including bone growth stimulation devices (e.g., CMF Ol1000, SpinalStim). Comparable as a broad incumbent offering overlapping PEMF/electrical stimulation capabilities within a much larger portfolio.
Emerging players
- Inovio Pharmaceuticals: DNA vaccine and gene therapy developer using electroporation delivery (CELLECTRA). Comparable to IGEA's gene therapy electroporation platform (CLINIPORATOR FULL, Genedrive) for nucleic acid vaccination.
- AngioDynamics: Medical device company with NanoKnife irreversible electroporation technology for tumor ablation. Adjacent to IGEA's reversible electroporation (Cliniporator) in the electroporation oncology space.
- OncoSec Medical: Biotech focused on intratumoral electroporation and gene delivery (ImmunoPulse/TAVO). Comparable to IGEA's Cliniporator electroporation platform for oncology and gene therapy applications.
Direct peers
- Bioventus: Orthobiologics and bone stimulation company with EXOGEN ultrasound (LIPUS-equivalent) and electrical stimulation products. Highly comparable to IGEA's FAST (LIPUS) and PEMF devices in clinical indication and care setting.
- Orthofix Medical: US-listed orthopedic medical device company with a leading bone growth stimulation (PEMF and direct current) portfolio. Directly comparable to IGEA's Biostim, Biostim SPT, and OsteoBit orthopaedic stimulation devices, addressing fracture healing, non-union, and spine fusion indications.
- Ito Co., Ltd. Japanese manufacturer of PEMF and physical therapy medical devices (e.g., Ito Ultralizer, PEMF bone healing devices). Closely comparable biophysical stimulation technology with overlap in orthopaedic indications.
- BTL Group: Medical device company offering PEMF-based devices (e.g., BTL-5110) for orthopaedics and rehabilitation, alongside physiotherapy and aesthetics devices. Direct competitor in biophysical electromagnetic therapy for musculoskeletal indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
IGEA S.p.A. social profiles
Digital presenceIGEA S.p.A. financial estimates
Financial estimateRevenue estimate
Valuation estimate
IGEA S.p.A. leadership team
Management profileNumber of profiles
Profiles4 records
IGEA S.p.A. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IGEA S.p.A. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IGEA S.p.A.
What does IGEA S.p.A. do?
IGEA S.p.A. develops, manufactures and sells proprietary biophysical therapy medical devices across three therapeutic divisions: Orthopaedic Therapies (Biostim®, OsteoSpine®, I-ONE®, Biostim® SPT, OsteoBit®, FAST®) using PEMF, CCEF and LIPUS physical stimuli to promote bone and cartilage healing; Electrochemotherapy (Cliniporator®, Cliniporator® Vitae) using reversible electroporation for treatment of solid tumours and vascular malformations; and Gene Therapies (CLINIPORATOR® FULL, Genedrive) using tissue electroporation for nucleic acid vaccine delivery. The devices are sold and rented to hospitals, clinics and orthopaedic treatment centers, primarily across Europe.
Is IGEA S.p.A. a public or private company?
IGEA S.p.A. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was IGEA S.p.A. founded?
IGEA S.p.A. was founded in 1982. It employs 101 to 250 people.
Where is IGEA S.p.A. based?
IGEA S.p.A. is headquartered in Carpi (MO), Italy, in the Europe region.
How does IGEA S.p.A. make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are device Rental.
Who are IGEA S.p.A.'s main competitors?
Broad incumbents on record are Stryker, Zimmer Biomet and Enovis (DJO Global). Emerging players are Inovio Pharmaceuticals, AngioDynamics and OncoSec Medical. Direct peers are Bioventus, Orthofix Medical, Ito Co., Ltd. and BTL Group.
Does IGEA S.p.A. have an API?
No public API is recorded for IGEA S.p.A..
What industry is IGEA S.p.A. in?
IGEA S.p.A.'s product category is Biophysical Therapy Medical Devices. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAKALAM, Pain Management (Spine & Musculoskeletal). Its NAICS code is 334510 and its SIC code is 3845.